Sandoz announced the acquisition of GSK's cephalosporin antibiotic business to expand its collection of antimicrobials. This acquisition allows Sandoz to increase its portfolio of antibiotics, which is beneficial for both Sandoz and the patients they serve. The acquisition also gives Sandoz access to GSK's patented technology, which will help them stay competitive in the industry.
In Europe, the European Commission approved the consolidation of Mylan and Upjohn between Pfizer and Mylan. Combining Mylan's generics market presence with Pfizer's branded market presence will enable the companies to create a new global healthcare leader.
Author Credits: Radhika Gupta, Shivam Bhutani